SciSparc Announces 1-for-21 Reverse Share Split

*TEL AVIV —* SciSparc Ltd., a specialty clinical-stage pharmaceutical
company focusing on the development of therapies to treat disorders and
rare diseases of the central nervous system, announced today that it
intends to effect a one-for-twenty one (1-for-21) reverse share split of
the Company’s issued and outstanding ordinary shares, no par value per
share, effective at the market open on July 3, 2025. The Ordinary Shares
will continue to trade on the Nasdaq Capital Market under the existing
trading symbol “SPRC” and will begin trading on a split-adjusted basis at
the market open on July 3, 2025. The new CUSIP number for the Ordinary
Shares following the Reverse Share Split will be M82618121.

The Reverse Share Split was approved by the Company’s shareholders at the
Company’s Annual General Meeting of Shareholders held on October 23, 2024,
to be effected at the board of directors’ discretion within the approved
parameters.

The Reverse Share Split will not result in an adjustment to the authorized
share capital of the Company under the Company’s amended and restated
articles of association, as currently in effect, which, as of June 24,
2025, consisted of 75,000,000 Ordinary Shares.

The Reverse Share Split will affect all shareholders uniformly and will not
alter any shareholder’s percentage of ownership interest in the Company’s
Ordinary Shares, except for minor changes due to the treatment of
fractional shares. The number of issued and outstanding Ordinary Shares
will be reduced from 11,225,751 Ordinary Shares to approximately 534,600
Ordinary Shares following the Reverse Share Split (subject to any further
adjustments due to the treatment of fractional shares). In accordance with
the Articles, no fractional Ordinary Shares will be issued as a result of
the Reverse Share Split and all fractional Ordinary Shares shall be rounded
to the nearest whole Ordinary Share, at the DTC participant level. In
addition, a proportionate adjustment will be made to the per share exercise
price and the number of shares issuable upon the exercise of all
outstanding options and warrants entitling the holders to purchase Ordinary
Shares. No fractional Ordinary Shares will be issued upon exercise of
warrants or options. As to any fraction of an Ordinary Share which a holder
would otherwise be entitled to purchase upon exercise, the Company will
round up to the nearest whole Ordinary Share, according to the terms of the
warrant or option.

Shareholders holding their shares in book-entry form, through a brokerage
account, or in “street name” are not required to take any action, as the
exchange will be processed automatically by their respective brokers or
custodians.
About SciSparc Ltd. (Nasdaq: SPRC)

SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by
an experienced team of senior executives and scientists. SciSparc’s focus
is on creating and enhancing a portfolio of technologies and assets based
on cannabinoid pharmaceuticals. With this focus, the Company is currently
engaged in the following drug development programs based on THC and/or
non-psychoactive cannabidiol: SCI-110 for the treatment of Tourette
Syndrome, for the treatment of Alzheimer’s disease and agitation; and
SCI-210 for the treatment of autism and status epilepticus. The Company
also owns a controlling interest in a subsidiary whose business focuses on
the sale of hemp seeds’ oil-based products on the Amazon.com Marketplace.